These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 15311726)
1. Improving lipid management--to titrate, combine or switch. Schuster H Int J Clin Pract; 2004 Jul; 58(7):689-94. PubMed ID: 15311726 [TBL] [Abstract][Full Text] [Related]
2. Optimizing LDL-C lowering with statins. McKenney JM Am J Ther; 2004; 11(1):54-9. PubMed ID: 14704596 [TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
4. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Levy DR; Pearson TA Clin Cardiol; 2005 Jul; 28(7):317-20. PubMed ID: 16075823 [TBL] [Abstract][Full Text] [Related]
5. Managing dyslipidemia in the high-risk patient. Stein EA Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720 [TBL] [Abstract][Full Text] [Related]
6. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Stein E Atheroscler Suppl; 2002 Apr; 2(4):19-23; discussion 23-5. PubMed ID: 11976073 [TBL] [Abstract][Full Text] [Related]
7. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
8. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948 [TBL] [Abstract][Full Text] [Related]
10. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. Olsson AG Am J Cardiol; 2001 Mar; 87(5A):33B-36B. PubMed ID: 11256849 [TBL] [Abstract][Full Text] [Related]
11. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129 [TBL] [Abstract][Full Text] [Related]
12. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
15. A new reality: achieving cholesterol-lowering goals in clinical practice. Gaw A Atheroscler Suppl; 2002 Apr; 2(4):5-8; discussion 8-11. PubMed ID: 11976071 [TBL] [Abstract][Full Text] [Related]
16. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study. Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS; Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098 [TBL] [Abstract][Full Text] [Related]
18. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192 [TBL] [Abstract][Full Text] [Related]
19. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. Lama S; Souraya D; Youssef F Int J Clin Pharm; 2017 Aug; 39(4):919-926. PubMed ID: 28523462 [TBL] [Abstract][Full Text] [Related]
20. Benefit on atherosclerosis of adding niacin in patients with low HDL-cholesterol taking a statin. Amsterdam EA Prev Cardiol; 2005; 8(2):130. PubMed ID: 15860992 [No Abstract] [Full Text] [Related] [Next] [New Search]